A $39 Million Grant for Hemophilia A Gene Therapy

Children’s Hospital of Philadelphia received an award of up to $38.9 million from ARPA-H for a five-year program developing personalized gene-editing therapies for rare liver-related genetic disorders, including hemophilia A. The program will explore base editing and prime editing delivered by lipid nanoparticles. This is early-stage research rather than a treatment people can receive now. 

Source: LA Kelley Communications, Inc., Communique, August 2026